Abbreviations: CCLE, chronic cutaneous lupus erythematosus; SCLE, subacute cutaneous lupus erythematosus; ANA, anti-nuclear antibodies.
Supplemental
Abbreviations: CLASI-A, cutaneous lupus activity and severity index-activity; CLASI-D, -damage; SCLE, subacute cutaneous lupus erythematosus; CLE, cutaneous lupus erythematosus; ANA, anti-nuclear antibodies; SLE, systemic lupus erythematosus.
a Goodness-of-fit statistics QIC and CIC were used to compare the expanded multivariable models to the original multivariable models (Table 2) . Lower values suggest a better fit. For the CLASI-A models, QIC was slightly lower for the expanded models compared to the original models (50%, 131 vs 139; 75%, 82.6 vs 85.2), while CIC was substantially higher (50%, 6.42 vs 3.54; 75%, 7.11 vs 3.79) . For the CLASI-D models, both QIC and CIC were higher for the expanded models compared to the original models (QIC: 20%, 183 vs 177; 40% 111 vs 109; CIC: 20%, 7.69 vs 4.17; 40%, 7.25 vs 4.08 This patient started smoking during the study. She is counted as a current smoker only during her second of two included visit-pairs. The patient had a 40% increase in CLASI-A during her first visit-pair (when she was not smoking) and no change in CLASI-A during her second visit-pair (when she was smoking). c Across all included study visits. d Started (or discontinued) medication class was defined as not taking (or taking) any medication from that class at the beginning of a visit-pair and taking (or not taking) any medication from that class at the end of a visit-pair. e Azathioprine, cyclophosphamide, cyclosporine, dapsone, methotrexate, mycophenolate mofetil or mycophenolic acid, prednisone, and thalidomide
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